Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPRIX vs JUNIOR STRENGTH ADVIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Short-term management of moderate to moderate-severe acute pain (FDA-approved indication)
FDA-labeled: Temporary relief of minor aches and pains (e.g., headache, toothache, menstrual cramps, muscle aches, backache),Fever reduction,Off-label: Osteoarthritis, rheumatoid arthritis (in higher doses),Off-label: Patent ductus arteriosus closure in neonates
Intranasal: 31.5 mg (1 spray) in one nostril, may repeat after 30 minutes; maximum 63 mg (2 sprays) per dose. Subsequent doses every 6-8 hours as needed; maximum 126 mg (4 sprays) per day.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.
Terminal elimination half-life is 5-6 hours in adults with normal renal function; may be prolonged to 13-14 hours in elderly patients and 15-20 hours in patients with renal impairment.
2-4 hours (terminal); prolonged in hepatic impairment and elderly.
Primarily hepatic via conjugation (glucuronidation) and oxidation (CYP2C9 minor). Metabolites are inactive.
Hepatic metabolism primarily via CYP2C9; also involves glucuronidation; major metabolites are hydroxylated and carboxylated forms.
Renal excretion of unchanged drug and metabolites; after intravenous administration, approximately 92% of the dose is recovered in urine (50% as unchanged ketorolac, 40% as glucuronide conjugates) and 6% in feces.
Primarily renal (90% as glucuronide conjugates and 10% unchanged); <5% biliary/fecal.
99% bound to plasma proteins, primarily albumin (saturable at high concentrations).
90-99% bound to albumin; concentration-dependent.
0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid.
0.1-0.2 L/kg (low, consistent with high protein binding).
Intranasal: approximately 75-80% relative to intravenous administration.
Oral: 85-95% (ibuprofen susp/liquid); 80-100% (tablets/capsules).
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-60 m L/min), reduce total daily dose by 50% and monitor for renal toxicity.
e GFR 30-60 m L/min: reduce dose by 50% or extend interval to q8-12h; e GFR <30 m L/min: avoid use.
Contraindicated in Child-Pugh Class C cirrhosis. For mild to moderate hepatic impairment (Child-Pugh A or B), reduce total daily dose by 50% and monitor for signs of bleeding or hepatic toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use.
Not recommended for use in pediatric patients (safety and efficacy not established).
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day (or 1200 mg/day) for children ≥6 months.
Elderly patients may have increased risk of GI bleeding and renal toxicity. Use lowest effective dose and shortest duration; monitor renal function and adjust dose based on estimated glomerular filtration rate (e GFR).
Start at lowest effective dose (200 mg q6-8h); maximum 1200 mg/day; monitor renal function and GI bleeding risk.
Risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk is increased with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.
No FDA boxed warning for JUNIOR STRENGTH ADVIL (ibuprofen). However, NSAIDs in general carry a boxed warning for cardiovascular thrombotic events and gastrointestinal bleeding.
Cardiovascular risk: May increase risk of serious cardiovascular thrombotic events.,Gastrointestinal risk: Can cause serious GI adverse events including bleeding, ulceration, and perforation.,Renal toxicity: Monitor renal function; avoid in patients with advanced renal disease.,Hepatic effects: Elevations in liver enzymes; discontinue if signs of hepatic injury occur.,Anaphylactoid reactions: Can occur in patients without prior exposure.,Pregnancy: Avoid in late pregnancy due to risk of premature closure of ductus arteriosus.
Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke,Gastrointestinal risk: Increased risk of GI bleeding, ulceration, and perforation,Renal effects: May cause renal impairment, especially in patients with pre-existing renal disease,Hypersensitivity reactions: Anaphylaxis, bronchospasm,Fluid retention and edema,Avoid use with other NSAIDs or in late pregnancy (risk of premature closure of ductus arteriosus)
Hypersensitivity to ketorolac or any NSAID,Active peptic ulcer disease or GI bleeding,Advanced renal impairment (creatinine clearance <30 m L/min),Patients at risk for bleeding or receiving anticoagulants,Labor and delivery (risk of fetal harm),Treatment of perioperative pain in CABG surgery,Concomitant use with other NSAIDs or aspirin,Intrathecal or epidural administration (contains alcohol)
Hypersensitivity to ibuprofen or any component of the formulation,Asthma, urticaria, or allergic-type reactions after aspirin or other NSAID use,Treatment of perioperative pain in coronary artery bypass graft (CABG) surgery,Use in children with chickenpox (due to increased risk of severe skin reactions)
No specific food interactions. Avoid alcohol as it may increase risk of GI bleeding. Take with food or milk to minimize GI upset.
Avoid alcohol: increases risk of GI bleeding. Limit caffeine as may increase side effects. Can be taken with food or milk to minimize GI irritation.
Pregnancy Category C. Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. No adequate studies in first two trimesters; use only if potential benefit justifies risk.
Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly needed; limited human data suggest low risk of major malformations but increased risk of miscarriage and cardiac defects.
Excreted in human milk in low amounts. M/P ratio not available. Consider risk of infant NSAID exposure; use with caution, especially in neonates.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Not expected to cause adverse effects in infants with short-term use at recommended doses. Avoid in nursing mothers breastfeeding preterm or low-birth-weight infants.
No specific dose adjustments recommended for pharmacokinetic changes in pregnancy. Use lowest effective dose for shortest duration.
No specific dose adjustment recommended in pregnancy. However, use lowest effective dose for shortest duration. In third trimester, avoid use unless benefit outweighs risk of fetal toxicity.
SPRIX (ketorolac tromethamine) is an NSAID nasal spray for acute pain. Use lowest effective dose for shortest duration. Avoid in patients with active peptic ulcer, recent GI bleeding, renal impairment (Cr Cl <30 m L/min), or at risk of bleeding. Contraindicated in patients with aspirin or NSAID allergy, and in patients with or at risk of intracranial bleeding. Monitor renal function and GI symptoms. Not for use in pediatric patients. Maximum duration is 5 days.
For pediatric patients, weight-based dosing is critical; typical dose is 5-10 mg/kg/dose every 6-8 hours. Avoid use in children with dehydration, bleeding disorders, or aspirin allergy. May mask signs of infection. Not recommended for children under 6 months.
Use exactly as prescribed; do not exceed 5 days of therapy.,Spray into nostril; do not sniff deeply after spraying.,Avoid alcohol and other NSAIDs while using this medication.,Seek medical help if you experience signs of bleeding, stomach pain, or allergic reaction.,Store at room temperature; do not refrigerate or freeze.,Tell your doctor about all other medications you take, especially blood thinners or other NSAIDs.
Give with food or milk to reduce stomach upset.,Do not exceed recommended dose; overdose can cause liver damage or gastrointestinal bleeding.,Do not use with other products containing ibuprofen or NSAIDs.,Shake suspension well before measuring dose using appropriate dosing device.,Stop use and consult doctor if symptoms worsen or new symptoms occur.,Keep out of reach of children; in case of overdose, contact Poison Control immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPRIX vs JUNIOR STRENGTH ADVIL, answered by our medical review team.
SPRIX is a NSAID Analgesic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. JUNIOR STRENGTH ADVIL is a NSAID Analgesic that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPRIX and JUNIOR STRENGTH ADVIL depend on the specific clinical indication. These are both NSAID Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPRIX is: Intranasal: 31.5 mg (1 spray) in one nostril, may repeat after 30 minutes; maximum 63 mg (2 sprays) per dose. Subsequent doses every 6-8 hours as needed; maximum 126 mg (4 sprays) per day.. The standard adult dose of JUNIOR STRENGTH ADVIL is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPRIX and JUNIOR STRENGTH ADVIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPRIX is classified as Category C. Pregnancy Category C. Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. No adequate studies in first two trimesters; use only if p. JUNIOR STRENGTH ADVIL is classified as Category C. Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly nee. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.